Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.27
+1.53 (15.71%)
Jul 7, 2025, 4:00 PM - Market closed

Zevra Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
61644527215830848
Upgrade
Market Cap Growth
68.25%63.82%71.57%-48.52%536.60%283.47%
Upgrade
Enterprise Value
61541623397178112
Upgrade
Last Close Price
11.278.346.554.598.7111.20
Upgrade
Forward PE
10.59----2.95
Upgrade
PS Ratio
13.7018.859.9015.5910.743.64
Upgrade
PB Ratio
15.0211.224.392.112.42-0.73
Upgrade
P/TBV Ratio
---2.112.42-
Upgrade
P/FCF Ratio
----29.76-
Upgrade
P/OCF Ratio
----29.47-
Upgrade
EV/Sales Ratio
15.1617.618.499.526.218.43
Upgrade
EV/EBITDA Ratio
----22.27-
Upgrade
EV/EBIT Ratio
----23.01-
Upgrade
EV/FCF Ratio
----17.20-
Upgrade
Debt / Equity Ratio
1.511.520.710.190.01-1.06
Upgrade
Debt / EBITDA Ratio
----0.18-
Upgrade
Debt / FCF Ratio
----0.16-
Upgrade
Asset Turnover
0.250.140.190.080.401.22
Upgrade
Quick Ratio
2.792.351.167.5826.920.90
Upgrade
Current Ratio
3.022.531.187.7227.201.11
Upgrade
Return on Equity (ROE)
-204.78%-207.84%-67.23%-26.48%-28.18%-
Upgrade
Return on Assets (ROA)
-27.73%-31.03%-21.55%-12.54%6.70%-27.52%
Upgrade
Return on Capital (ROIC)
-45.85%-52.90%-31.82%-14.28%7.27%-62.18%
Upgrade
Return on Capital Employed (ROCE)
----6.00%-
Upgrade
Earnings Yield
-14.93%-23.70%-16.95%-16.90%-2.78%-26.41%
Upgrade
FCF Yield
-10.03%-15.65%-12.45%-11.88%3.36%-4.08%
Upgrade
Buyback Yield / Dilution
-32.32%-30.46%-2.79%-15.87%-647.72%-114.79%
Upgrade
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q